Clinical Trial Update: Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib with or without hydroxychloroquine in chemo-naive advanced non-small cell lung cancer with EGFR mutations, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2017-06-06